Frölich, L. (2019). Open-label, multicenter, phase III extension study of idalopirdine as adjunctive to donepezil for the treatment of mild-moderate alzheimer’s disease. Journal of Alzheimer's disease, 67(1), . https://doi.org/10.3233/JAD-180595
Chicago-Zitierstil (17. Ausg.)Frölich, Lutz. "Open-label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-moderate Alzheimer’s Disease." Journal of Alzheimer's Disease 67, no. 1 (2019). https://doi.org/10.3233/JAD-180595.
MLA-Zitierstil (9. Ausg.)Frölich, Lutz. "Open-label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-moderate Alzheimer’s Disease." Journal of Alzheimer's Disease, vol. 67, no. 1, 2019, https://doi.org/10.3233/JAD-180595.